Clinical Trial Update: Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of Vactosertib and Imatinib for advanced Desmoid Tumor / Aggressive Fibromatosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Desmoid Tumor
• Desmoid-type Fibromatosis

Drugs mentioned

• Gleevec (Imatinib)
• Vactosertib (Vactosertib)

Snippet

Sponsor: MedPacto, Inc. | Conditions: Dermoid | Phase 2 | Status: WITHDRAWN